Ankylosing Spondylitis
📧 Sign up to get email alerts when something new happens for Ankylosing Spondylitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-06-01Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis [Phase 2]
Phase 2 clinical trial evaluating safety and efficacy of upadacitinib in adults with active ankylosing spondylitis has completed and results…
-
CLINICAL_TRIALS trial_result · 2021-05-13Clinical Trial Update: Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy [Phase 4]
Phase 4 clinical trial comparing eupatilin and rebamipide for prevention of gastroenteropathy, sponsored by Seoul National University Borama…
-
FDA approval · 2021-04-30FDA Approved: SULINDAC — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for sulindac from Sun Pharmaceutical Industries, Inc., authorizing changes to its labeling and/o…
-
FDA approval · 2021-04-28FDA Approved: INDOCIN — Supplemental Application (Zyla Life Sciences US LLC)
The FDA has approved a supplemental application for INDOCIN (indomethacin) by Zyla Life Sciences US LLC.
-
FDA approval · 2021-04-28FDA Approved: NAPROXEN — Supplemental Application (Acella Pharmaceuticals, LLC)
The FDA approved a supplemental application for Naproxen filed by Acella Pharmaceuticals, LLC, updating the product's approval status.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-04-28FDA Approved: INDOMETHACIN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's supplemental application for Indomethacin, approving a generic Indomethacin product.
-
FDA approval · 2021-04-28FDA Approved: INDOMETHACIN — Supplemental Application (XLCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Indomethacin from XLCare Pharmaceuticals Inc. This approval updates the drug's existing FDA appr…
-
FDA approval · 2021-03-31FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Diclofenac Sodium from Actavis Pharma, Inc. under ANDA074514. The approval covers an updated for…
-
FDA approval · 2021-03-26FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for diclofenac sodium (a generic NSAID).
-
FDA approval · 2021-02-24FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approval of a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ from Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Efficacy and Safety Study of SUNPG1622 [Phase 2]
Phase 2 clinical trial update for SUNPG1622 in active ankylosing spondylitis or non-radiographic axial spondyloarthritis; study terminated w…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis [Phase 4]
Phase 4 trial updating the effect of adding NSAIDs to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in …
-
CLINICAL_TRIALS withdrawal · 2021-01-11Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy [Phase 3]
Phase 3 trial evaluating filgotinib in biologic-naïve ankylosing spondylitis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-01-11Clinical Trial Update: Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS) [Phase 3]
Phase 3 trial update on tofacitinib for active ankylosing spondylitis with posted results.
-
CLINICAL_TRIALS withdrawal · 2021-01-11Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy [Phase 3]
Phase 3 trial evaluating filgotinib in active ankylosing spondylitis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-12-30Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis [Phase 3]
Phase 3 study of secukinumab in Ankylosing Spondylitis completed; results posted in 2020.
-
FDA approval · 2020-12-03FDA Approved: CELECOXIB — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original ANDA for Celecoxib from ScieGen Pharmaceuticals, a generic version of the COX-2 inhibitor used for pain relief. It…
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis [Phase 2]
Phase 2 trial evaluating different doses of bimekizumab in active ankylosing spondylitis completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-03Clinical Trial Update: Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients [Phase 4]
Phase 4 trial updates biomarkers associated with the efficacy of an anti-TNFα agent in ankylosing spondylitis.
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis [Phase 4]
Phase 4 clinical trial update evaluating efficacy and NSAID-sparing effect of secukinumab in ankylosing spondylitis; results posted after co…
-
FDA approval · 2020-09-24FDA Approved: DICLOFENAC SODIUM AND MISOPROSTOL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for the diclofenac sodium and misoprostol product from Mylan Pharmaceuticals, updating its label…
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis [Phase 4]
A Phase 4 clinical trial evaluating non-steroidal anti-inflammatory drugs in axial spondyloarthritis was terminated with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: Bawei Shenqi Pill in the Treatment of Ankylosing Spondylitis [Phase 2, Phase 3]
Clinical trial update for Bawei Shenqi Pill in ankylosing spondylitis, currently in Phase 2/Phase 3 with status unknown.
-
FDA approval · 2020-07-28FDA Approved: NAPROXEN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for Naproxen from Glenmark Pharmaceuticals to update the labeling for the generic product under the …
-
FDA approval · 2020-07-06FDA Approved: HULIO — Original Application (Biocon Biologics Inc)
FDA approved HULIO (adalimumab-fkjp) from Biocon Biologics Inc via an original Biologics License Application, a biosimilar to adalimumab. Th…